Cagrilintide
2.4 mg · Weekly
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 2 cited sources
Evidence
- Human Studies
- 8
- Animal Studies
- 15
- Clinical Status
- Investigational
- Confidence
- Moderate
- Long-Term Safety
- Established short/medium-term in Phase 2/3 trials; not yet FDA approved, so no long-term post-approval surveillance data exists yet
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
Cagrilintide is a long-acting amylin receptor agonist that promotes satiety through a different pathway than GLP-1 drugs, and is being developed in combination with semaglutide (as "CagriSema") for weight management. As of this writing it has not received FDA approval on its own or in combination.
Common Protocols
- Weekly subcutaneous injection, titrated up over months in published trials — dosing outside a trial or prescription is not established
Side Effects
- GI side effects (nausea, vomiting, diarrhea, constipation) similar to GLP-1 drugs, common especially during titration
- Injection site reaction
Interactions
- May compound GI side effects when combined with GLP-1/GIP-class medications, which is also the basis of its intended combination use — clinician supervision matters
Practical Details
- Cost
- $$$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Garvey WT et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. PMID 40544433.
- Ahmed M et al. (2026). Efficacy and safety of cagrilintide and CagriSema versus semaglutide: systematic review and meta-analysis. Diabetes Obes Metab. PMID 41834765.
Search the Research
Cagrilintide FAQ
What is the typical Cagrilintide dosage?
Commonly reported protocols: Weekly subcutaneous injection, titrated up over months in published trials — dosing outside a trial or prescription is not established. Our reference entry uses 2.4 mg, Weekly. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of Cagrilintide?
Reported side effects include: GI side effects (nausea, vomiting, diarrhea, constipation) similar to GLP-1 drugs, common especially during titration; Injection site reaction.
Is Cagrilintide FDA approved?
Cagrilintide is still being studied in clinical trials and is not FDA approved. Products sold outside those trials are not the same as a regulated drug.
How much research is there on Cagrilintide?
Our evidence profile counts roughly 8 human and 15 animal studies, with moderate overall confidence. Long-term safety: Established short/medium-term in Phase 2/3 trials; not yet FDA approved, so no long-term post-approval surveillance data exists yet.
Does Cagrilintide interact with other drugs or supplements?
May compound GI side effects when combined with GLP-1/GIP-class medications, which is also the basis of its intended combination use — clinician supervision matters.
How do I reconstitute Cagrilintide?
A common setup is a 10 mg vial mixed with 2 mL of bacteriostatic water, which puts a 2.4 mg dose at about 48 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Related compounds
Long-acting amylin analogue; studied combined with semaglutide as CagriSema